December 28, 2022
4 min watch
Save
VIDEO: Bispecifics here to stay for treatment of multiple myeloma
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
NEW ORLEANS — In this video perspective, Nikhil C. Munshi, MD, discusses presentations from the ASH Annual Meeting and Exposition that focus on advances in bispecific antibody treatments for patients with multiple myeloma.
New data on teclistamab, elranatamab, alnuctamab and two studies that looked at combinations of bispecific therapies are highlighted.
"Bispecifics are here to stay," Munshi, a professor of medicine at Harvard Medical School, said.
"They are becoming an important part of our treatment, currently as a fifth line and beyond, but very strong. In combination we will be utilizing them much earlier on in the treatment," he said.
References:
- Chari A, et al. Abstract 157. Presented at: ASH Annual Meeting and Exposition; Dec. 10-13, 2022; New Orleans.
- Grosicki S, et al. Abstract 1921. Presented at: ASH Annual Meeting and Exposition; Dec. 10-13, 2022; New Orleans.
- Searle E, et al. Abstract 160. Presented at: ASH Annual Meeting and Exposition; Dec. 10-13, 2022; New Orleans.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Disclosures:
Munshi reports serving on advisory boards or consulting for Adaptive, AbbVie, Amgen, BMS, Celgene, GSK, Janssen, Karyopharm, Legend, Novartis, OncoPep, Pfizer and Takeda, current equity holder in publicly traded company.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.